A Phase 1 Dose Finding Study of the gFOLFOXIRITAX Regimen Using UGT1A1 Genotype-directed Irinotecan With Fluorouracil, Leucovorin, Oxaliplatin and Taxotere in Patients With Untreated Advanced Upper Gastrointestinal Adenocarcinomas: The I-FLOAT Study
Latest Information Update: 30 Aug 2023
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms I-FLOAT
- 25 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.
- 06 Jun 2023 Results (Data from 6/30/22 to 1/1/23, n=27) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 26 Apr 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.